To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
TOKYO (Reuters) – Japan’s Nikkei share average ticked higher on Tuesday in largely directionless trade, as investors braced for the finale of the local earnings season and the release of closely watched U.S. inflation figures the following day.
The Nikkei .N225 finished the day up 0.46% at 38,356.06, with 125 of its 225 components rising versus 100 that fell, following a relatively calm session. The broader Topix rose 0.25%.
Earnings produced some stand-out winners and losers, including heavyweight startup investor SoftBank Group , which rallied 4.34% to make it the Nikkei’s biggest support.
Furukawa Electric surged almost 19% to pace advancers, while refiner ENEOS Holdings jumped more than 10% after reporting results during the afternoon session.
At the other end, construction company Kajima and chemical company Tosoh Corp were the two leading decliners, each sliding close to 9%.
Some 600 companies report over the course of Tuesday, and about the same number report Wednesday, when the current earnings season largely comes to a close.
“There are a lot of individual drivers, but unfortunately none that give an overall direction to the market,” Kazuo Kamitani, an equities strategist at Nomura Securities said.
Without additional catalysts, the Nikkei will fluctuate narrowly between the five- and 25-day moving averages at around 38,170 and 38,450 respectively, Kamitani projected.
Daiwa Securities was another notable loser on Tuesday, dropping 6.82% on news that it would invest 51.9 billion yen ($331.78 million) in Aozora Bank , making it the biggest shareholder. Aozora Bank shares eased 0.91%.
Drugmaker Shionogi fell more than 4% after saying its COVID treatment pill failed in a trial to show a statistically significant reduction in symptoms.
Peer Chugai Pharmaceutical lost 3.38% following a successful trial of a rival hemophilia treatment from Novo Nordisk NOVOb.CO.
